Pulmatrix, a clinical-stage biopharmaceutical company, announced a merger agreement with Cullgen Inc., a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE platform to discover and advance therapeutics for the treatment of cancer and other diseases.

临床阶段生物制药公司Pulmatrix宣布与私人控股的临床阶段生物制药公司Cullgen Inc.达成合并协议，该公司应用其专有的靶向蛋白质降解uSMITE平台来发现和推进治疗癌症和其他疾病的疗法。

Cullgen utilizes its proprietary technology platform, uSMITE, featuring novel E3 ligands, to build the next generation of targeted protein degraders and degrader-antibody conjugates ('DACs'). In 2023 Cullgen completed a Series C financing led by AstraZeneca-CICC Venture Capital Partnership, and also announced a strategic partnership with Astellas Pharma Inc.About the Proposed Transaction; Subject to the terms and conditions of the merger agreement, and upon the closing of the merger, pre-merger Pulmatrix stockholders are expected to own approximately 3.6% of the combined company, and pre-merger Cullgen stockholders are expected to own approximately 96.4% of the combined company which will operate under the name Cullgen Inc., be headquartered in San Diego, CA and trade on The Nasdaq Capital Market (Nasdaq).

Cullgen利用其专有技术平台uSMITE，以新型E3配体为特征，构建下一代靶向蛋白质降解物和降解物-抗体偶联物（“DAC”）。2023年，Cullgen完成了由阿斯利康-中金公司风险投资合伙公司牵头的C系列融资，并宣布与Astellas Pharma Inc.就拟议交易建立战略合作伙伴关系；根据合并协议的条款和条件，合并结束后，合并前的Pulmatrix股东预计将拥有合并公司约3.6%的股份，合并前的Cullgen股东预计将拥有合并公司约96.4%的股份，该公司将以Cullgen Inc.的名义运营，总部位于加利福尼亚州圣地亚哥，并在纳斯达克资本市场（Nasdaq）进行交易。

Pulmatrix stockholders will also receive a special cash dividend to the extent that Pulmatrix's net cash at closing exceeds $2.5 million, subject to certain adjustments..

Pulmatrix股东还将获得特别现金股息，前提是Pulmatrix在交割时的净现金超过250万美元，但需进行某些调整。。

Type: industry

类型：工业